<DOC>
	<DOCNO>NCT00754572</DOCNO>
	<brief_summary>This single arm , open-label study ass safety efficacy regar reduction sign symptoms treatment tocilizumab combinatio n methotrexate , patient moderate severe active rheumatoid arthr itis . Patients receive tocilizumab 8mg/kg iv , every 4 week methotrexat e 10-25mg weekly . The anticipated time study treatment 3-12 month , th e target sample size &lt; 500 individual .</brief_summary>
	<brief_title>A Study Assess Effect Tocilizumab Plus Methotrexate Safety Signs Symptoms Patients With Moderate Severe Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>patient &gt; =18 year moderate severe active RA least 6 month ; swell joint count &gt; =6 ( 66 joint count ) tender joint count &gt; =8 ( 68 joint count ) screening ; inadequate response stable dose MTX ; patient reproductive potential must use reliable mean contraception . rheumatic autoimmune disease RA ; patient functional class IV RA ; diagnosis juvenile idiopathic rheumatoid arthritis age 16 history current inflammatory joint disease RA ; prior treatment failure antitumor necrosis factor agent ; pregnant breastfeeding woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>